Next-gen biotechs pursue 'undruggable' targets

A crop of up-and-coming developers, including Anchor Therapeutics, Aileron Therapeutics, Forma Therapeutics and NeurAxon--are among the new wave of biotechs that seek to successfully hit molecular targets that Big Pharma has missed for decades. "[Going after undruggable targets] is a risk we take," Rick Jones, CEO of Anchor Therapeutics, tells TheScientist. "People have been banging on it for so long that they have gotten tired of it or just assume it can't be done." Read more

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.